Despite growing interest in the use of cannabis for the treatment of cancer-related symptoms, there are limited studies that have assessed the use pattern, type, and mode of delivery of cannabis products used by cancer survivors. This study describes the current state of the use pattern, product type, and mode of delivery of cannabis used by cancer survivors. This was a cross-sectional study of cancer survivors from 41 U.S. states who received treatment at the largest NCI-designated comprehensive cancer center. The weighted prevalence of the use patterns, product types, and modes of delivery of cannabis used by cancer survivors was estimated. A total of 1886 cancer survivors were included in the study, with 915 (48% [95% CI: 45–51]) reporting ever using cannabis. Of survivors who had ever used cannabis, 36% (95% CI: 33–40) were current users. Among survivors who reported cannabis use after diagnosis, 40% used cannabis during and after cancer treatment, 35% used cannabis during treatment, and 25% used cannabis after completing their cancer treatment. Additionally, 48% of survivors reported an increase in cannabis use since cancer diagnosis. The commonest types of cannabis products used by cancer survivors were dry leaf cannabis (71%), cannabidiol (CBD) oil (46%), and cannabis candy (40%). Moreover, cancer survivors frequently used baked goods (32%), creams and gels (21%), and tinctures (18%). Furthermore, among ever users, the predominant mode of use was cannabis inhalation/smoking (69%) compared to eating/drinking (59%). More so, the common mode of inhalation/smoking of cannabis products were rolled cannabis cigarettes (79%), pipes (36%), water pipes (34%), vaporizers or vapes (14%), and e-cigarette devices (14%). A substantial number of cancer survivors use cannabis during cancer treatment, with increased use following cancer diagnosis. The forms and modes of delivery of cannabis varied among survivors, with most survivors inhaling or smoking cannabis. There is a need to educate healthcare providers (HCPs) and survivors on current evidence of cannabis use and strengthen cannabis regulatory frameworks to optimize benefits and minimize adverse events from cannabis use during cancer treatment.
尽管人们对使用大麻治疗癌症相关症状的兴趣日益增长，但针对癌症幸存者使用大麻产品的模式、类型及给药方式的研究仍十分有限。本研究旨在描述癌症幸存者使用大麻的模式、产品类型及给药方式的现状。本研究采用横断面调查方法，研究对象为来自美国41个州、在全美最大的国家癌症研究所指定综合癌症中心接受治疗的癌症幸存者。研究估算了癌症幸存者使用大麻的模式、产品类型及给药方式的加权流行率。研究共纳入1886名癌症幸存者，其中915人（48% [95% CI: 45–51]）报告曾使用大麻。在曾使用大麻的幸存者中，36%（95% CI: 33–40）为当前使用者。在确诊后使用大麻的幸存者中，40%在癌症治疗期间及治疗后使用大麻，35%仅在治疗期间使用，25%在完成治疗后使用。此外，48%的幸存者报告自确诊后增加了大麻使用量。癌症幸存者最常用的大麻产品类型包括干叶大麻（71%）、大麻二酚（CBD）油（46%）和大麻糖果（40%）。同时，烘焙食品（32%）、乳霜凝胶（21%）和酊剂（18%）也较常使用。在曾使用者中，主要使用方式为吸入/吸食（69%），高于口服/饮用（59%）。吸入/吸食大麻产品的常见方式包括手卷大麻烟（79%）、烟斗（36%）、水烟枪（34%）、雾化器（14%）和电子烟设备（14%）。大量癌症幸存者在治疗期间使用大麻，且确诊后使用量有所增加。大麻的使用形式和给药方式在幸存者中存在差异，多数幸存者通过吸入或吸食方式使用。有必要对医疗保健提供者和幸存者进行当前大麻使用证据的宣教，并加强大麻监管框架，以优化癌症治疗期间大麻使用的益处并减少不良事件。
Cannabis Use among Cancer Survivors: Use Pattern, Product Type, and Timing of Use
肿瘤(癌症)患者之家